Supplementary Table 1. Final outcomes* of perinatal hepatitis B prevention program by year, 2002–2021

Birth year of infants	Subject (n)	HBsAg (–)/ anti-HBs (+), n (%)	HBsAg (–)/ anti-HBs (–), n (%)	HBsAg (+)/ anti-HBs (–), n (%)	HBsAg (+)/ anti-HBs (+), n (%)
Total	154,478	145,385 (94.1)	5,469 (3.5)	3,488 (2.3)	136 (0.1)
2002	2,779	2,524 (90.8)	140 (5.0)	113 (4.1)	2 (0.1)
2003	8,901	8,142 (91.5)	435 (4.9)	316 (3.6)	8 (0.1)
2004	9,079	8,346 (91.9)	386 (4.3)	340 (3.7)	7 (0.1)
2005	8,105	7,599 (93.8)	251 (3.1)	250 (3.1)	5 (0.1)
2006	8,460	7,830 (92.6)	380 (4.5)	248 (2.9)	2 (0.0)
2007	9,461	8,719 (92.2)	489 (5.2)	245 (2.6)	8 (0.1)
2008	9,041	8,400 (92.9)	404 (4.5)	232 (2.6)	5 (0.1)
2009	8,553	7,813 (91.3)	477 (5.6)	255 (3.0)	8 (0.1)
2010	8,265	7,692 (93.1)	368 (4.5)	200 (2.4)	5 (0.1)
2011	8,243	7,667 (93.0)	386 (4.7)	178 (2.2)	12 (0.1)
2012	9,462	8,896 (94.0)	394 (4.2)	159 (1.7)	13 (0.1)
2013	10,001	9,463 (94.6)	355 (3.5)	170 (1.7)	13 (0.1)
2014	10,920	10,487 (96.0)	233 (2.1)	196 (1.8)	4 (0.0)
2015	10,394	9,985 (96.1)	251 (2.4)	146 (1.4)	12 (0.1)
2016	9,078	8,775 (96.7)	158 (1.7)	136 (1.5)	9 (0.1)
2017	7,046	6,791 (96.4)	150 (2.1)	99 (1.4)	6 (0.1)
2018	6,016	5,848 (97.2)	76 (1.3)	86 (1.4)	6 (0.1)
2019	4,797	4,685 (97.7)	47 (1.0)	60 (1.3)	5 (0.1)
2020	3,455	3,368 (97.5)	46 (1.3)	36 (1.0)	5 (0.1)
2021	2,422	2,355 (97.2)	43 (1.8)	23 (0.9)	1 (0.0)

Anti-HBs, antibody to hepatitis B surface antigen; HBsAg, hepatitis B surface antigen.
*HBsAg (–)/anti-HBs (+), indicating successful immunization outcome; HBsAg (–) / anti-HBs (–), suggesting vaccine non-response; HBsAg (+)/anti-HBs (–), indicating hepatitis B virus infection; and HBsAg (+)/anti-HBs (+), potentially representing surface gene mutant hepatitis B virus infection or false-positive test results.

 https://doi.org/10.3350/cmh.2025.0214